In addition, regardless of which of the above phenomena underlie the elevated GFAP immunoreactivity in SMA model systems, its causative mechanisms remain unclear, as is whether the astrocytic aberration might be targeted in the development of SMA therapeutics. Here, GFAP is linked to proximal spinal muscular atrophy.